Onco-Innovations Announces Closing of Private Placement

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) closed a non-brokered private placement on October 27, 2025, issuing 1,428,570 units at $1.40 per unit for aggregate gross proceeds of $2,000,000. Each unit comprises one common share and one-half of one warrant; warrants are exercisable at $2.00 per share for 36 months. The company paid finders $119,999.94 and issued 85,714 warrants, and issued 14,286 administrative shares for services. Proceeds are for general corporate and working capital purposes, including operational, R&D and investor relations objectives. All securities are subject to a four-month-and-one-day statutory hold and are not registered for sale in the United States.

Positive

• Raised $2,000,000 in gross proceeds
• Issued 1,428,570 units at $1.40 per unit
• Warrants exercisable at $2.00 for 36 months

Negative

• Issued 1,442,856 new shares including administrative shares
• Paid $119,999.94 in finder fees, reducing net proceeds
• Issued 85,714 additional warrants to finders increasing dilution

VANCOUVER, BC / ACCESS Newswire / October 27, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that it has closed its previously-announced (see news release dated October 14, 2025) non-brokered private placement (the "Private Placement"), issuing 1,428,570 units of the Company (the "Units") at a price of $1.40 per Unit, for aggregate gross proceeds of $2,000,000. Each Unit consists of one common share (each a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"), with each Warrant entitling the holder to purchase one Share at a price of $2.00 for a period of thirty-six (36) months.

The proceeds from the Private Placement will be used for general corporate and working capital purposes, including in pursuit of the Company's operational, research and development, and investor relations objectives.

In connection with the closing of the Private Placement, the Company paid, in aggregate, $119,999.94 and issued 85,714Warrants to certain finders in consideration for their introducing subscribers.

The Company has also issued 14,286 Shares ("Administrative Shares") of the Company to an arm's-length third party, in consideration for administrative services rendered in connection with the Private Placement.

Pursuant to applicable securities laws, all securities issued in connection with the Private Placement will be subject to a statutory hold period of four months and one day.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of proceeds thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include that the proceeds from the Private Placement may be used other than as currently contemplated and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

How much did Onco-Innovations (ONNVF) raise in the October 27, 2025 private placement?

Onco-Innovations raised $2,000,000 in gross proceeds from the private placement.

How many units and shares did Onco-Innovations (ONNVF) issue in the private placement?

The company issued 1,428,570 units, each including one share, plus 14,286 administrative shares.

What are the warrant terms from Onco-Innovations (ONNVF) private placement?

Warrants were issued at one‑half per unit, exercisable at $2.00 per share for 36 months.

How much were finders paid in Onco-Innovations (ONNVF) financing?

The company paid finders $119,999.94 and issued 85,714 warrants as consideration.

What will Onco-Innovations (ONNVF) use the private placement proceeds for?

Proceeds are designated for general corporate and working capital, including operations, R&D, and investor relations.

Are the securities from Onco-Innovations (ONNVF) private placement immediately tradable?

No; all securities are subject to a four-month-and-one-day statutory hold under applicable securities laws.